Craft

LungLife AI

Stock Price

£0.1

2024-10-29

Market Capitalization

£2.6 M

2024-10-29

Revenue

$46 K

FY, 2023

LungLife AI Summary

Company Summary

Overview
LungLife AI (formerly Cynvenio) is a company using AI to provide lung cancer diagnostic solutions. It is focused on cancer diagnosis and management through molecular analysis of biomarkers in blood. The company provides tests that can be used as an aid in diagnosis for patients with early-stage disease as well as a treatment stratification and monitoring tool for late-stage lung cancer.
Type
Public
Status
Active
Founded
2009
HQ
Thousand Oaks, CA, US | view all locations
Website
https://www.lunglifeai.com/
Cybersecurity rating
Sectors

Key People

  • Paul Pagano, Chief Executive Officer, Executive Director

  • David Anderson, Chief Financial Officer, Executive Director

    • Roy Davis

      Roy Davis, Non-Executive Chairman

    • Andrew Boteler, Non-Executive Director

      Operating MetricsView all

      Trademarks (US)

      3

      Sep, 2022

      LocationsView all

      1 location detected

      • Thousand Oaks, CA HQ

        United States

        2545 W Hillcrest Dr #140

      LungLife AI Financials

      Summary Financials

      Revenue (FY, 2023)
      $46.0K
      Gross profit (FY, 2023)
      $46.0K
      Net income (FY, 2023)
      ($5.4M)
      Cash (FY, 2023)
      $2.7M
      EBIT (FY, 2023)
      ($5.6M)
      Enterprise value
      $228.0K

      Footer menu